{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Number of participants with Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Number of participants with Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Tumor response rate was based on Response Evaluation Criteria in Solid Tumors (RECIST).\n\nComplete Response (CR): Disappearance of all target lesions.\n\nPartial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.","groups":[{"description":"Temozolomide capsules 150 mg/m\\^2 daily on a 7-day on/7-day off schedule for each 28-day cycle. Temozolomide is the only treatment group, and and all participants received the same dosing regimen.","id":"OG000","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"Population for the primary outcome measure is all evaluable participants per protocol definition (82 participants).\n\nComplete response is defined as disappearance of all target lesions.\n\nPartial response is defined as at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.","reportingStatus":"POSTED","timeFrame":"From start of treatment until participant's disease progression, intolerable toxicity or death, which ever comes first","title":"Tumor Responses (Complete and Partial Response)","type":"PRIMARY","unitOfMeasure":"Participants"}